Press release: Umeå, November 22, 2021. Lipum AB (publ) (“Lipum”) announces that Flerie Invest AB has acquired all of Almi Invest AB's shares and warrants in Lipum. The transaction took place outside the marketplace. As a new major shareholder in Lipum, Flerie Invest will be part of the Nomination Committee.
Flerie Invest AB is a reputable investment company with active ownership in biotechnology and pharmaceuticals. The company is controlled by Thomas Eldered, who was previously CEO and co-founder of Recipharm. Flerie Invest has solid experience in building companies within the pharmaceutical industry and after the acquisition of Almi Invest's shares, their ownership has increased to approximately 9.4% of votes and capital in Lipum.
Almi Invest AB, a state-owned seed investor, was in 2016 the first investor in Lipum. They have since provided organizational support and participated in capital raising. In connection with Lipum's listing on Nasdaq First North in April 2021, Almi Invest made a commitment for a lock-up for six months, but also declared that they normally liquidate listed holdings.
"We are facing the next step in Lipum's development and plan for the start of clinical trials in 2022. Then, of course, it is extremely valuable to have active owners who with industrial experience can support that development." - says Einar Pontén, CEO.
The transaction means that Flerie Invest as a major shareholder will be part of the Nomination Committee and represented by Carl-Johan Spak. Other members of the Nomination Committee are Olle Hernell, who represents the founders, Adam Dahlberg and the Company's Chairman of the Board, Ulf Björklund.
Shareholders are welcome to submit proposals and views to the Nomination Committee via email to <firstname.lastname@example.org>. To ensure that proposals can be considered, these must be received in good time before the annual general meeting, but no later than 31 January 2022.
For further information, please contact:
Lipum AB (publ) is a biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in late preclinical stage supported by solid data for the rare disease juvenile idiopathic arthritis and rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum’s unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission, email: email@example.com, phone: +46 8 503 000 50.